Loading
A phase 1/2 trial of OSE2101 in non-small-cell lung cancer and small-cell lung cancer, run by OSE Immunotherapeutics, now recruiting.
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05751798 by OSE Immunotherapeutics, with 41 participants planned, started 2022-12-20 and due to reach its primary completion in 2029-12. Interventions recorded: Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg, Part B: OSE-279 600 mg and OSE2101, Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive. Conditions listed: Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/